Commercializing cell therapies through end-to-end supply chain solutions

The complexity of cell therapy production and delivery demands supply chain solutions that are both agile and compliant. This session explores how end-to-end integration—from raw material sourcing to logistics and patient delivery—can streamline commercialization while meeting stringent regulatory and quality standards.

Key takeaways

• Analyze how end-to-end supply chain design supports scalable and compliant cell therapy delivery.
• Examine key logistical and operational challenges unique to autologous and allogeneic models.
• Identify digital and data-driven tools that enhance visibility and traceability.
• Discuss collaboration strategies between CDMOs, logistics providers, and therapy developers.
• Understand how supply chain innovation can accelerate time to market and improve patient access.